Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398803 | 0.82 | ALDH1A1 (0.56) | PTGER4BRD4ALDH1A1ALDH3A1 | |
| SCHEMBL3995363 | 0.81 | BRD4 (0.55) | PTGER4BRD4ALDH1A1ALDH3A1 | |
| SCHEMBL3997877 | 0.81 | PKM (0.53) | ALDH1A1PKM | |
| SCHEMBL4969247 | 0.81 | HTR6 (0.51) | GBA1PTGER4HTR6ALDH1A1PKM | |
| SCHEMBL3996701 | 0.78 | BRD4 (0.51) | PTGER4BRD4ALDH1A1ALDH3A1PARG | |
| SCHEMBL3997818 | 0.78 | ALDH1A1 (0.53) | PTGER4BRD4ALDH1A1ALDH3A1 | |
| SCHEMBL4969033 | 0.76 | FFAR4 (0.49) | GBA1HTR6ALDH1A1PKMALDH3A1 | |
| SCHEMBL4967027 | 0.75 | FFAR4 (0.48) | GBA1HTR6ALDH1A1PKMALDH3A1 | |
| SCHEMBL8028185 | 0.75 | NPC1 (0.54) | NPC1HTR6ALDH1A1PKM | |
| SCHEMBL1700398 | 0.75 | BRD4 (0.48) | PTGER4BRD4ALDH1A1PKMALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | GBA1 116/4885PTGER4 647/4885FFAR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.